ONCBIOMUNE PHARMACEUTICALS INC (OTCMKTS:OBMP) Could Burn Your Long Portfolio After More Shorts

October 11, 2018 - By Hazel Jackson

OncBioMune Pharmaceuticals, Inc. (OTCMKTS:OBMP) Logo

The stock of ONCBIOMUNE PHARMACEUTICALS INC (OTCMKTS:OBMP) registered an increase of 302.86% in short interest. OBMP’s total short interest was 14,100 shares in October as published by FINRA. Its up 302.86% from 3,500 shares, reported previously.

The stock increased 14.21% or $0.0027 during the last trading session, reaching $0.0217. About shares traded. OncBioMune Pharmaceuticals, Inc. (OTCMKTS:OBMP) has 0.00% since October 11, 2017 and is . It has underperformed by 15.62% the S&P500.

OncBioMune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops cancer immunotherapy products. The company has market cap of $5.11 million. The firm has proprietary rights to a breast and prostate patent vaccine; and a process for the growth of cancer tumors. It currently has negative earnings. The Company’s lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>